PFE Overview
Upcoming Projects (PFE)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (PFE)
-
Q4 #3 Prescriber check-in with a dermatologist to discuss the standard of care and the use of LITFULO (ritlecitinib) to treat severe alopecia areata.
Ticker: PFE
Executed On: Nov 14, 2024 at 01:00 PM EST -
Q4: A Third Prescriber check in on the use of Cibinqo (abrocitinib) to treat atopic dermatitis
Ticker: PFE
Executed On: Nov 13, 2024 at 05:00 PM EST -
Q4: A Second Prescriber check in on the use of Cibinqo (abrocitinib) to treat atopic dermatitis
Ticker: PFE
Executed On: Nov 12, 2024 at 02:30 PM EST -
A Third Look: Discussing the recent approval of Pfizer’s RSV vaccine ABRYSVO® for adults aged 18 to 59 at increased risk for disease based on the results from the pivotal Phase 3 MONeT clinical trial.
Ticker: PFE
Executed On: Nov 12, 2024 at 12:00 PM EST -
Q4: Prescriber check in on the use of Cibinqo (abrocitinib) to treat atopic dermatitis
Ticker: PFE
Executed On: Nov 12, 2024 at 12:00 PM EST -
A Third Look: Discussing the recent approval and potential of HYMPAVZI (marstacimab-hncq) for patients with Hemophilia A or B
Ticker: PFE
Executed On: Nov 12, 2024 at 11:30 AM EST -
A Second Look: Discussing the recent approval of Pfizer’s RSV vaccine ABRYSVO® for adults aged 18 to 59 at increased risk for disease based on the results from the pivotal Phase 3 MONeT clinical trial.
Ticker: PFE
Executed On: Nov 12, 2024 at 11:00 AM EST -
Discussing the recent approval of Pfizer’s RSV vaccine ABRYSVO® for adults aged 18 to 59 at increased risk for disease based on the results from the pivotal Phase 3 MONeT clinical trial
Ticker: PFE
Executed On: Nov 08, 2024 at 12:00 PM EST -
A Second Look: Discussing the recent approval and potential of HYMPAVZI (marstacimab-hncq) for patients with Hemophilia A or B.
Ticker: PFE
Executed On: Nov 07, 2024 at 04:00 PM EST -
A Second View: Looking into the recent decision by Pfizer to remove its sickle cell disease medication OXBRYTA (voxelotor) from the market.
Tickers: PFE, FULC
Executed On: Nov 07, 2024 at 01:00 PM EST -
A Third Perspective Discussing the expanding market opportunity with regard to direct to consumer platforms in the pharmaceutical space.
Tickers: PFE, LLY, VKTX, HIMS
Executed On: Nov 05, 2024 at 02:15 PM EST -
Looking into the recent decision by Pfizer to remove its sickle cell disease medication OXBRYTA (voxelotor) from the market.
Tickers: PFE, FULC
Executed On: Oct 31, 2024 at 10:00 AM EDT -
Q4 #2 Prescriber check-in with a dermatologist to discuss the standard of care and the use of LITFULO (ritlecitinib) to treat severe alopecia areata.
Ticker: PFE
Executed On: Oct 30, 2024 at 09:30 AM EDT -
A second look: Revisiting the HELIOS-B data for vutrisiran in ATTR-CM following publication in NEJM and presentation at ESC
Tickers: ALNY, BBIO, PFE
Executed On: Oct 22, 2024 at 03:00 PM EDT -
Discussing the recent approval and potential of HYMPAVZI (marstacimab-hncq) for patients with Hemophilia A or B.
Ticker: PFE
Executed On: Oct 22, 2024 at 02:00 PM EDT -
A third look: Revisiting the HELIOS-B data for vutrisiran in ATTR-CM following publication in NEJM and presentation at ESC
Tickers: ALNY, BBIO, PFE
Executed On: Oct 15, 2024 at 05:00 PM EDT -
Q4 #1 Prescriber check-in with a dermatologist to discuss the standard of care and the use of LITFULO (ritlecitinib) to treat severe alopecia areata.
Ticker: PFE
Executed On: Oct 07, 2024 at 06:30 PM EDT -
A Third Prescriber check in on the use of Cibinqo (abrocitinib) to treat atopic dermatitis
Ticker: PFE
Executed On: Oct 02, 2024 at 12:00 PM EDT -
A Second Prescriber check in on the use of Cibinqo (abrocitinib) to treat atopic dermatitis
Ticker: PFE
Executed On: Sep 26, 2024 at 05:00 PM EDT -
A Second Perspective Discussing the expanding market opportunity with regard to direct to consumer platforms in the pharmaceutical space.
Tickers: PFE, LLY, VKTX, HIMS
Executed On: Sep 18, 2024 at 09:00 AM EDT -
Discussing the expanding market opportunity with regard to direct to consumer platforms in the pharmaceutical space.
Tickers: LLY, PFE, VKTX, HIMS
Executed On: Sep 17, 2024 at 09:00 AM EDT -
Speaking on the potential of Pfizer's gene therapy candidate for hemophilia a
Ticker: PFE
Executed On: Sep 13, 2024 at 04:00 PM EDT -
Revisiting the HELIOS-B data for vutrisiran in ATTR-CM following publication in NEJM and presentation at ESC
Tickers: ALNY, BBIO, PFE
Executed On: Sep 12, 2024 at 12:30 PM EDT -
A Third Opinion: Discussing the current vaccine landscape and the potential of Pfizer's mRNA combination vaccine against influenza and COVID-19.
Tickers: PFE, BNTX
Executed On: Sep 11, 2024 at 02:30 PM EDT -
A Third Opinion: Discussing the topline data from the phase 3 MONeT clinical trial of Pfizer's RSV vaccine ABRYSVO in patients who are immunocompromised
Ticker: PFE
Executed On: Aug 27, 2024 at 11:00 AM EDT -
A Second Opinion: Discussing the current vaccine landscape and the potential of Pfizer's mRNA combination vaccine against influenza and COVID-19.
Tickers: PFE, BNTX
Executed On: Aug 23, 2024 at 10:00 AM EDT -
A Second Opinion: Discussing the topline data from the phase 3 MONeT clinical trial of Pfizer's RSV vaccine ABRYSVO in patients who are immunocompromised
Ticker: PFE
Executed On: Aug 23, 2024 at 09:00 AM EDT -
Discussing the current vaccine landscape and the potential of Pfizer's mRNA combination vaccine against influenza and COVID-19.
Tickers: PFE, BNTX
Executed On: Aug 22, 2024 at 11:00 AM EDT -
Discussing the topline data from the phase 3 MONeT clinical trial of Pfizer's RSV vaccine ABRYSVO in patients who are immunocompromised
Ticker: PFE
Executed On: Aug 15, 2024 at 03:40 PM EDT -
A Third Prescriber check-in with a dermatologist to discuss the standard of care and the use of LITFULO (ritlecitinib) to treat severe alopecia areata.
Ticker: PFE
Executed On: Aug 14, 2024 at 09:00 AM EDT -
Prescriber check in on the use of Cibinqo (abrocitinib) to treat atopic dermatitis
Ticker: PFE
Executed On: Aug 08, 2024 at 02:30 PM EDT -
A Second Prescriber check-in with a dermatologist to discuss the standard of care and the use of LITFULO (ritlecitinib) to treat severe alopecia areata.
Ticker: PFE
Executed On: Aug 01, 2024 at 04:00 PM EDT -
Prescriber check-in with a dermatologist to discuss the standard of care and the use of LITFULO (ritlecitinib) to treat severe alopecia areata.
Ticker: PFE
Executed On: Jul 29, 2024 at 09:00 AM EDT -
A Second Look: Discussing the potential of Pfizer’s Gene Therapy, BEQVEZ (fidanacogene elaparvovec-dzkt), for adults with hemophilia B
Ticker: PFE
Executed On: Jul 10, 2024 at 04:30 PM EDT -
Discussing the potential of Pfizer’s Gene Therapy, BEQVEZ (fidanacogene elaparvovec-dzkt), for adults with hemophilia B
Ticker: PFE
Executed On: Jul 03, 2024 at 03:00 PM EDT -
A Third Look: Discussing the the potential of ABRYSVO for adults 18 to 59 years of age at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD).
Ticker: PFE
Executed On: May 03, 2024 at 08:00 AM EDT -
A Second Look: Discussing the the potential of ABRYSVO for adults 18 to 59 years of age at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD).
Ticker: PFE
Executed On: May 02, 2024 at 05:30 PM EDT -
Discussing the the potential of ABRYSVO for adults 18 to 59 years of age at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD).
Ticker: PFE
Executed On: Apr 30, 2024 at 01:30 PM EDT -
Discussing the LATITUDE phase III interim trial data on Cabenuva (cabotegravir, rilpivirine) for treatment of HIV
Tickers: GSK, PFE
Executed On: Feb 28, 2024 at 10:30 AM EST -
Investigating the results from the Phase 3 BENEGENE-2 study of Pfizer's fidanacogene elaparvovec for hemophilia B
Ticker: PFE
Executed On: Feb 13, 2024 at 12:00 PM EST -
A Third Look: Discussing the current standard of care and the use of Pfizer's Litfulo as a treatment for alopecia.
Ticker: PFE
Executed On: Jan 08, 2024 at 11:00 AM EST -
A Second Look: Discussing the current standard of care and the use of Pfizer's Litfulo as a treatment for alopecia.
Ticker: PFE
Executed On: Jan 08, 2024 at 09:00 AM EST -
A third look at the RSV current treatment landscape including available vaccines from GSK (Arexvy) and Pfizer (Abryvso)
Tickers: PFE, GSK
Executed On: Dec 22, 2023 at 10:00 AM EST -
Discussing the current standard of care and the use of Pfizer's Litfulo as a treatment for alopecia.
Ticker: PFE
Executed On: Dec 21, 2023 at 05:30 PM EST -
A second look at the RSV current treatment landscape including available vaccines from GSK (Arexvy) and Pfizer (Abryvso)
Tickers: PFE, GSK
Executed On: Dec 14, 2023 at 12:30 PM EST -
A look at the RSV current treatment landscape including available vaccines from GSK (Arexvy) and Pfizer (Abryvso)
Tickers: PFE, GSK
Executed On: Dec 13, 2023 at 10:30 AM EST -
A Third Look: Discussing the potential of Pfizer and Astellas' XTANDI which was recently approved by U.S. FDA in earlier prostate cancer treatment based on the Phase 3 EMBARK trial
Tickers: PFE, ALPMY
Executed On: Dec 11, 2023 at 12:00 PM EST -
A Second Look: Discussing the potential of Pfizer and Astellas' XTANDI which was recently approved by U.S. FDA in earlier prostate cancer treatment based on the Phase 3 EMBARK trial
Tickers: PFE, ALPMY
Executed On: Dec 05, 2023 at 09:00 AM EST -
Discussing the potential of Pfizer and Astellas' XTANDI which was recently approved by U.S. FDA in earlier prostate cancer treatment based on the Phase 3 EMBARK trial
Tickers: PFE, ALPMY
Executed On: Nov 29, 2023 at 12:00 PM EST -
A Second Opinion: Reviewing the potential of Pfizers etrasimod for ulcerative colitis
Ticker: PFE
Executed On: Nov 15, 2023 at 05:00 PM EST -
A Third Opinion: Investigating Pfizer's recently approved pentavalent meningococcal vaccine Penbraya.
Ticker: PFE
Executed On: Nov 14, 2023 at 04:00 PM EST -
A Second Opinion: Investigating Pfizer's recently approved pentavalent meningococcal vaccine Penbraya.
Ticker: PFE
Executed On: Nov 09, 2023 at 03:30 PM EST -
Reviewing the potential of Pfizers etrasimod for ulcerative colitis
Ticker: PFE
Executed On: Nov 02, 2023 at 12:00 PM EDT -
Investigating Pfizer's recently approved pentavalent meningococcal vaccine Penbraya.
Ticker: PFE
Executed On: Nov 01, 2023 at 09:00 AM EDT -
A Third Look: Discussing the current treatment landscape and use of oral medications for migraines with a Neurologist.
Tickers: PFE, ABBV
Executed On: Oct 26, 2023 at 05:00 PM EDT -
A Second Look: Discussing the current treatment landscape and use of oral medications for migraines.
Tickers: PFE, ABBV
Executed On: Oct 25, 2023 at 03:30 PM EDT -
Discussing the current treatment landscape and use of oral medications for migraines.
Tickers: PFE, ABBV
Executed On: Oct 19, 2023 at 12:00 PM EDT -
Examining the standard of care and the potential of VLA15 after the positive Phase 2 booster results for Lyme Disease vaccine candidate VLA15 by Pfizer and Valneva SE
Tickers: PFE, VALN
Executed On: Oct 12, 2023 at 02:35 PM EDT -
A Third Opinion: Discussing the standard of care and the potential of the two updated Covid-19 booster shots from Pfizer/BioNTech and Moderna for this fall season
Tickers: PFE, MRNA
Executed On: Oct 03, 2023 at 04:00 PM EDT -
A Second Opinion: Discussing the standard of care and the potential of the two updated Covid-19 booster shots from Pfizer/BioNTech and Moderna for this fall season
Tickers: PFE, MRNA
Executed On: Sep 28, 2023 at 01:35 PM EDT -
A Second Opinion: An updated look at the potential of Acoramidis following Part B results of the Attribute-CM trial
Tickers: BBIO, PFE
Executed On: Sep 21, 2023 at 12:00 PM EDT -
Discussing the standard of care and the potential of the two updated Covid-19 booster shots from Pfizer/BioNTech and Moderna for this fall season.
Tickers: PFE, MRNA
Executed On: Sep 20, 2023 at 12:00 PM EDT -
A Second Opinion: Discussing the FDA approval of Pfizer's Abrysvo RSV maternal vaccine for the prevention of lower respiratory tract disease caused by RSV in infants from birth up to six months of age
Ticker: PFE
Executed On: Sep 18, 2023 at 03:00 PM EDT -
Discussing the FDA approval of Pfizer's Abrysvo RSV maternal vaccine for the prevention of lower respiratory tract disease caused by RSV in infants from birth up to six months of age
Ticker: PFE
Executed On: Sep 13, 2023 at 03:00 PM EDT -
An updated look at the potential of Acoramidis following Part B results of the Attribute-CM trial
Tickers: BBIO, PFE
Executed On: Sep 01, 2023 at 09:30 AM EDT -
A third discussion on the treatment landscape and the potential of ELREXFIO (elranatamab-bcmm) in patients with multiple myeloma in light of the recent FDA accelerated approval.
Ticker: PFE
Executed On: Aug 25, 2023 at 10:30 AM EDT -
A second discussion on the treatment landscape and the potential of ELREXFIO (elranatamab-bcmm) in patients with multiple myeloma in light of the recent FDA accelerated approval.
Ticker: PFE
Executed On: Aug 24, 2023 at 06:30 PM EDT -
A discussion on the treatment landscape and the potential of ELREXFIO (elranatamab-bcmm) in patients with multiple myeloma in light of the recent FDA accelerated approval.
Ticker: PFE
Executed On: Aug 24, 2023 at 02:00 PM EDT -
A Third View: Checking in with a prescriber of ZAVZPRET (zavegepant) from Pfizer for the acute treatment of Migraines
Ticker: PFE
Executed On: Aug 22, 2023 at 03:00 PM EDT -
A Second View: Checking in with a prescriber of ZAVZPRET (zavegepant) from Pfizer for the acute treatment of Migraines
Ticker: PFE
Executed On: Aug 17, 2023 at 06:00 PM EDT -
Checking in with a prescriber of ZAVZPRET (zavegepant) from Pfizer for the acute treatment of Migraines
Ticker: PFE
Executed On: Aug 11, 2023 at 12:00 PM EDT -
A Third Look: Discussing the potential of Pfizer's NGENLA (somatrogon-ghla), a once-weekly human growth hormone analog injection, for children aged 3 and older with growth hormone deficiency
Ticker: PFE
Executed On: Aug 09, 2023 at 11:00 AM EDT -
A Second Look: Discussing the potential of Pfizer's NGENLA (somatrogon-ghla), a once-weekly human growth hormone analog injection, for children aged 3 and older with growth hormone deficiency
Ticker: PFE
Executed On: Aug 07, 2023 at 03:20 PM EDT -
Discussing the potential of Pfizer's NGENLA (somatrogon-ghla), a once-weekly human growth hormone analog injection, for children aged 3 and older with growth hormone deficiency
Ticker: PFE
Executed On: Aug 02, 2023 at 05:30 PM EDT -
A third look: Investigating the phase 3 EMBARK study data on XTANDI (enzalutamide) in combination with leuprolide in patients with nmHSPC and nmCSPC.
Ticker: PFE
Executed On: Jul 28, 2023 at 11:30 AM EDT -
A second look: Investigating the phase 3 EMBARK study data on XTANDI (enzalutamide) in combination with leuprolide in patients with nmHSPC and nmCSPC.
Ticker: PFE
Executed On: Jul 27, 2023 at 05:00 PM EDT -
A Second Opinion: Discussing Acoramidis following Part B results of the Attribute-CM trial
Tickers: BBIO, PFE
Executed On: Jul 27, 2023 at 01:00 PM EDT -
Discussing Acoramidis following Part B results of the Attribute-CM trial
Tickers: BBIO, PFE
Executed On: Jul 19, 2023 at 04:30 PM EDT -
Investigating the phase 3 EMBARK study data on XTANDI (enzalutamide) in combination with leuprolide in patients with nmHSPC and nmCSPC.
Ticker: PFE
Executed On: Jul 19, 2023 at 03:00 PM EDT -
A third look: Discussing Pfizer's maternal RSV vaccine to expectant mothers for the protection of newborns against Respiratory syncytial virus with an OBGYN.
Ticker: PFE
Executed On: Jul 17, 2023 at 02:00 PM EDT -
A Third Opinion: Discussing the standard of care and the potential of Pfizer's Litfulo (Ritlecitinib) which was recently approved by the FDA for treatment severe alopecia areata
Ticker: PFE
Executed On: Jul 12, 2023 at 10:00 AM EDT -
A Second Opinion: Discussing the standard of care and the potential of Pfizer's Litfulo (Ritlecitinib) which was recently approved by the FDA for treatment severe alopecia areata
Ticker: PFE
Executed On: Jul 10, 2023 at 12:30 PM EDT -
Discussing the standard of care and the potential of Pfizer's Litfulo (Ritlecitinib) which was recently approved by the FDA for treatment severe alopecia areata
Ticker: PFE
Executed On: Jun 30, 2023 at 11:00 AM EDT -
Discussing the potential of Pfizer's Marstacimab for the treatment of hemophilia A and B
Ticker: PFE
Executed On: Jun 23, 2023 at 06:00 PM EDT -
A Third Look: Discussing PAXLOVID prescribing patterns and patient experience with a general practitioner.
Ticker: PFE
Executed On: Jun 23, 2023 at 02:00 PM EDT -
A Final Opinion: Digging into the phase 2 TITRATE Clinical trial data on Pfizer's GLP-1 agonist candidate danuglipron (PF-06882961) in patients with type 2 diabetes and obesity
Ticker: PFE
Executed On: Jun 16, 2023 at 10:00 AM EDT -
A second look: Discussing Pfizer's maternal RSV vaccine to expectant mothers for the protection of newborns against Respiratory syncytial virus with an OBGYN.
Ticker: PFE
Executed On: Jun 13, 2023 at 12:00 PM EDT -
A third look: Digging into the phase 2 TITRATE Clinical trial data on Pfizer's GLP-1 agonist candidate danuglipron (PF-06882961) in patients with type 2 diabetes and obesity.
Ticker: PFE
Executed On: Jun 12, 2023 at 02:00 PM EDT -
A third opinion: Discussing the potential of Prevnar20, a vaccine approved for the prevention of invasive disease caused by 20 Streptococcus pneumoniae strains in individuals 6 weeks and older.
Ticker: PFE
Executed On: Jun 12, 2023 at 11:00 AM EDT -
A second look: Digging into the phase 2 TITRATE Clinical trial data on Pfizer's GLP-1 agonist candidate danuglipron (PF-06882961) in patients with type 2 diabetes and obesity.
Ticker: PFE
Executed On: Jun 09, 2023 at 03:40 PM EDT -
Discussing Pfizer's maternal RSV vaccine to expectant mothers for the protection of newborns against Respiratory syncytial virus with an OBGYN.
Ticker: PFE
Executed On: Jun 09, 2023 at 11:15 AM EDT -
A Second Look: Discussing PAXLOVID prescribing patterns and patient experience with a general practitioner.
Ticker: PFE
Executed On: Jun 07, 2023 at 06:00 PM EDT -
Digging into the phase 2 TITRATE Clinical trial data on Pfizer's GLP-1 agonist candidate danuglipron (PF-06882961) in patients with type 2 diabetes and obesity.
Ticker: PFE
Executed On: Jun 07, 2023 at 10:30 AM EDT -
Discussing PAXLOVID prescribing patterns and patient experience with a general practitioner.
Ticker: PFE
Executed On: Jun 01, 2023 at 12:00 PM EDT -
A second opinion: Discussing the potential of Prevnar20, a vaccine approved for the prevention of invasive disease caused by 20 Streptococcus pneumoniae strains in individuals 6 weeks and older.
Ticker: PFE
Executed On: May 23, 2023 at 09:00 AM EDT -
Discussing the potential of Prevnar20, a vaccine approved for the prevention of invasive disease caused by 20 Streptococcus pneumoniae strains in individuals 6 weeks and older.
Ticker: PFE
Executed On: May 12, 2023 at 09:00 AM EDT -
A Second View: Discussing the recent FDA approval of migraine nasal spray Zavzpret by Pfizer
Ticker: PFE
Executed On: Mar 23, 2023 at 09:00 AM EDT -
Discussing the recent FDA approval of migraine nasal spray Zavzpret by Pfizer
Ticker: PFE
Executed On: Mar 16, 2023 at 03:30 PM EDT -
A Second Look: Re-examining the safety of JAK inhibitors such as Xeljanz (tofacitinib) by Pfizer for the treatment of chronic inflammatory disorders.
Ticker: PFE
Executed On: Dec 20, 2022 at 10:00 AM EST -
Re-examining the safety of JAK inhibitors such Xeljanz (tofacitinib) by Pfizer for the treatment of chronic inflammatory disorders.
Ticker: PFE
Executed On: Nov 18, 2022 at 02:00 PM EST -
A second look: Discussing the phase 3 development program for maternal immunization with RSV vaccine
Ticker: PFE
Executed On: Nov 17, 2022 at 01:00 PM EST -
Examining the standard of care and new therapies in development including Pfizer's Talzenna (talazoparib) for the treatment of Prostate Cancer
Ticker: PFE
Executed On: Nov 15, 2022 at 08:00 AM EST -
A third discussion of the new covid vaccines targeting omicron variant, with a focused look at the potential of Ocugen's first in class nasal vaccine
Tickers: OCGN, PFE, MRNA, JNJ
Executed On: Nov 09, 2022 at 11:00 AM EST -
A look at the interim results from the P2 trial evaluating darovasertib(IDE196) and crizotinib synthetic lethal combination in metastatic uveal melanoma patients
Tickers: IDYA, PFE, IMCR
Executed On: Nov 01, 2022 at 03:00 PM EDT -
Discussing the current standard of care and the potential of VLA15, a multivalent recombinant protein vaccine candidate that targets six serotypes of Borrelia currently in development by Valneva and Pfizer.
Tickers: VALN, PFE
Executed On: Oct 31, 2022 at 12:00 PM EDT -
A second discussion of the new covid vaccines targeting omicron variant, with a focused look at the potential of Ocugen's first in class nasal vaccine
Tickers: OCGN, PFE, MRNA, JNJ
Executed On: Oct 27, 2022 at 11:30 AM EDT -
A fourth look: Discussing the potential of Patisiran in patients with ATTR Amyloidosis with Cardiomyopathy based on the recent data presented from the APOLLO-B Phase 3 Study
Tickers: ALNY, PFE
Executed On: Oct 21, 2022 at 10:30 AM EDT -
Discussing the new covid vaccines targeting omicron variant, with a focused look at the potential of Ocugen's first in class nasal vaccine
Tickers: OCGN, PFE, MRNA
Executed On: Oct 17, 2022 at 02:00 PM EDT -
A Fourth Check-in on prescribing pattern on Cibinqo treating atopic dermatitis
Ticker: PFE
Executed On: Oct 14, 2022 at 11:30 AM EDT -
A Third Check-in on prescribing pattern on Cibinqo treating atopic dermatitis
Ticker: PFE
Executed On: Oct 13, 2022 at 07:00 PM EDT -
A Second Check-in on prescribing pattern on Cibinqo treating atopic dermatitis
Ticker: PFE
Executed On: Oct 13, 2022 at 05:00 PM EDT -
A third look: Discussing the potential of Patisiran in patients with ATTR Amyloidosis with Cardiomyopathy based on the recent data presented from the APOLLO-B Phase 3 Study
Tickers: ALNY, PFE
Executed On: Oct 13, 2022 at 04:00 PM EDT -
A First Check-in on prescribing pattern on Cibinqo treating atopic dermatitis
Ticker: PFE
Executed On: Oct 12, 2022 at 04:00 PM EDT -
A second look: Discussing the potential of Patisiran in patients with ATTR Amyloidosis with Cardiomyopathy based on the recent data presented from the APOLLO-B Phase 3 Study
Tickers: ALNY, IONS, PFE
Executed On: Oct 12, 2022 at 02:00 PM EDT -
Discussing the potential of Obe-cel(AUTO1), a CD19 CAR T cell therapy being investigated for treatment in adult patients with acute lymphoblastic leukemia(ALL) and it's ongoing Phase 1/2 FELIX trial
Tickers: AUTL, AMGN, GILD, PFE
Executed On: Oct 07, 2022 at 02:00 PM EDT -
Discussing the phase 3 development program for maternal immunization with RSV vaccine
Ticker: PFE
Executed On: Oct 06, 2022 at 01:00 PM EDT -
Examining the clinical landscape of renal disease and the potential of anticoagulant therapies in this space for the prevention of cardiovascular events, including Merck's MK-2060.
Tickers: MRK, PFE, BMY
Executed On: Oct 03, 2022 at 02:00 PM EDT -
A look at the data presented at the ESMO 2022 Conference for the CXCR2 antagonist, AZD5069, in combination with enzalutamide for patients with metastatic castration resistant prostate cancer(mCRPC)
Tickers: AZN, PFE
Executed On: Sep 16, 2022 at 04:00 PM EDT -
Discussing the safety and efficacy of the new covid vaccines targeting omicron variant
Tickers: MRNA, AZN, PFE
Executed On: Sep 09, 2022 at 05:30 PM EDT -
A Third Look: Discussing the standard of care and use of Myfembree in treating endometriosis
Tickers: PFE, MYOV
Executed On: Aug 19, 2022 at 03:00 PM EDT -
A Second Look: Discussing the standard of care and use of Myfembree in treating endometriosis
Tickers: PFE, MYOV
Executed On: Aug 18, 2022 at 09:00 AM EDT -
A Final look: Understanding the impact, use, and prescribing patterns for XELJANZ (tofacitinib) in Rheumatoid Arthritis.
Ticker: PFE
Executed On: Aug 17, 2022 at 09:00 AM EDT -
A Third look: Understanding the impact, use, and prescribing patterns for XELJANZ (tofacitinib) in Rheumatoid Arthritis.
Ticker: PFE
Executed On: Aug 15, 2022 at 05:00 PM EDT -
Discussing the standard of care and use of Myfembree in treating endometriosis
Tickers: PFE, MYOV
Executed On: Aug 10, 2022 at 04:30 PM EDT -
A Second Look at Pfizer's oral COVID-19 antiviral Paxlovid
Ticker: PFE
Executed On: Aug 02, 2022 at 12:00 PM EDT -
A Look at Pfizer's oral COVID-19 antiviral Paxlovid
Ticker: PFE
Executed On: Aug 02, 2022 at 11:00 AM EDT -
A second look: Understanding the impact, use, and prescribing patterns for XELJANZ (tofacitinib) in Rheumatoid Arthritis.
Ticker: PFE
Executed On: Jul 28, 2022 at 01:00 PM EDT -
Understanding the impact, use, and prescribing patterns for XELJANZ (tofacitinib) in Rheumatoid Arthritis.
Ticker: PFE
Executed On: Jul 22, 2022 at 11:00 AM EDT -
A Final look at the use of Veklury and Paxlovid in Pediatric Covid patients
Tickers: PFE, GILD
Executed On: Jun 14, 2022 at 04:30 PM EDT -
A third look at the use of Veklury and Paxlovid in Pediatric Covid patients
Tickers: PFE, GILD
Executed On: Jun 02, 2022 at 02:30 PM EDT -
A second look at the use of Veklury and Paxlovid in Pediatric Covid patients
Tickers: PFE, GILD
Executed On: Jun 01, 2022 at 01:00 PM EDT -
A look at the use of Veklury and Paxlovid in Pediatric Covid patients
Tickers: PFE, GILD
Executed On: May 31, 2022 at 03:00 PM EDT -
An updated view on JAKi prescribing patterns in autoimmune conditions
Ticker: PFE
Executed On: May 24, 2022 at 05:00 PM EDT -
A Fourth Opinion: Discussing the potential of Sisunatovir for the treatment of Respiratory Syncytial Virus (RSV)
Ticker: PFE
Executed On: Apr 14, 2022 at 11:00 AM EDT -
Discussing the potential of Sisunatovir for the treatment of Respiratory Syncytial Virus (RSV).
Ticker: PFE
Executed On: Apr 14, 2022 at 09:30 AM EDT -
A Third Opinion: Discussing the potential of Sisunatovir for the treatment of Respiratory Syncytial Virus (RSV).
Ticker: PFE
Executed On: Apr 12, 2022 at 12:00 PM EDT -
A Second Opinion: Discussing the potential of Sisunatovir for the treatment of Respiratory Syncytial Virus (RSV).
Ticker: PFE
Executed On: Apr 11, 2022 at 12:00 PM EDT -
A Second Look: Discussing the recent label update for HIV treatment, Cabenuva (cabotegravir, rilpivirine)
Tickers: GSK, PFE
Executed On: Mar 29, 2022 at 11:00 AM EDT -
Discussing the recent label update for HIV treatment, Cabenuva (cabotegravir, rilpivirine)
Tickers: GSK, PFE
Executed On: Mar 28, 2022 at 04:30 PM EDT -
A Third View: Discussing the future of COVID vaccination (the current COVID vaccines, use of boosters, and new vaccines on the horizon.)
Tickers: PFE, MRK
Executed On: Jan 27, 2022 at 12:00 PM EST -
A Second Look: Discussing the future of COVID vaccination (the current COVID vaccines, use of boosters, and new vaccines on the horizon.)
Tickers: PFE, MRK
Executed On: Jan 25, 2022 at 10:00 AM EST -
Discussing the future of COVID vaccination (the current COVID vaccines, use of boosters, and new vaccines on the horizon.)
Tickers: PFE, MRK
Executed On: Jan 19, 2022 at 09:30 AM EST -
A look at Acoramidis following failure of Part A of Attribute-CM trial
Tickers: BBIO, PFE
Executed On: Jan 18, 2022 at 12:00 PM EST
Upcoming & Overdue Catalysts (PFE)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (PFE)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
